ixazomib citrate · Takeda Pharms Usa · NDA 208462
Ninlaro
Earliest generic entry, as listed · earliest of 3 marketed strengths
20 Nov 2029
Blocked by patent: US 7442830.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7442830 | substance, product, use U-2434 | 20 Nov 2029 |
| US 8859504 | substance, product | 16 Jun 2029 |
| US 9175017 | use U-2434 | 16 Jun 2029 |
| US 7687662 | substance, product | 6 Aug 2027 |
| US 8003819 | substance, product, use U-2434 | 6 Aug 2027 |
| US 8530694 | substance, product, use U-2434 | 6 Aug 2027 |
| US 8871745 | use U-2434 | 6 Aug 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208462 · 001 · RLD | capsule, oral | EQ 2.3MG BASE | 20 Nov 2029 |
| 208462 · 002 · RLD | capsule, oral | EQ 3MG BASE | 20 Nov 2029 |
| 208462 · 003 · RLD | capsule, oral | EQ 4MG BASE | 20 Nov 2029 |